Last updated: 11/07/2018 14:49:49
A multicentre, double-blind, placebo-controlled, parallel group, comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone with concomitant oral therapy with sulphonylurea when administered for 26 weeks to patients withtype 2 diabetes and who are…
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multicentre, double-blind, placebo-controlled, parallel group, comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone with concomitant oral therapy with sulphonylurea when administered for 26 weeks to patients withtype 2 diabetes and who are…
Trial description: A multicentre, double-blind, placebo-controlled, parallel group, comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone with concomitant oral therapy with sulphonylurea when administered for 26 weeks to patients withtype 2 diabetes and who are…
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Barnett AH, Grant PJ, Hitman GA, et al. Indo-Asian Trial Investigators. Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabetic Medicine 2003; 20:387–393
Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone is effective in patients of Indo-Asian ethnic origin with type 2 diabetes. Diabetes UK Annual Professional Meeting. Glasgow, UK, 4–6 April 2001. Diabetic Medicine 2001; 18 (Suppl. 2):Abstract A40.
Medical condition
Diabetes Mellitus, Type 2
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
May 1999 to Invalid Date
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website